Protagonist Therapeutics (NasdaqGM:PTGX) - Share price, News & Analysis

PTGX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

PTGX Stock Overview

Rewards

Revenue is forecast to grow 64.55% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Protagonist Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Protagonist Therapeutics
Historical stock prices
Current Share Price	US$7.70
52 Week High	US$50.54
52 Week Low	US$7.39
Beta	2.58
1 Month Change	-59.28%
3 Month Change	-67.01%
1 Year Change	-77.90%
3 Year Change	-29.23%
5 Year Change	-34.86%
Change since IPO	-34.19%

Recent News & Updates

May 11

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Celebrations may be in order for Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders, with the analysts...

Shareholder Returns

	PTGX	US Biotechs	US Market
7D	-10.6%	-3.2%	-4.0%
1Y	-77.9%	-22.1%	-13.2%

Return vs Industry: PTGX underperformed the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: PTGX underperformed the US Market which returned -12.3% over the past year.

Price Volatility

Is PTGX's price volatile compared to industry and market?
PTGX volatility
PTGX Average Weekly Movement	17.9%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: PTGX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: PTGX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	122	Dinesh Patel	https://www.protagonist-inc.com

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Fundamentals Summary

How do Protagonist Therapeutics's earnings and revenue compare to its market cap?
PTGX fundamental statistics
Market Cap	US$374.65m
Earnings (TTM)	-US$122.48m
Revenue (TTM)	US$46.89m

8.0x

P/S Ratio

-3.1x

P/E Ratio

Is PTGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTGX income statement (TTM)
Revenue	US$46.89m
Cost of Revenue	US$0
Gross Profit	US$46.89m
Other Expenses	US$169.37m
Earnings	-US$122.48m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.52
Gross Margin	100.00%
Net Profit Margin	-261.21%
Debt/Equity Ratio	0%

How did PTGX perform over the long term?

See historical performance and comparison

Valuation

Is Protagonist Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.24x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: PTGX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.

PE vs Market: PTGX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTGX's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: PTGX is good value based on its Price-To-Book Ratio (1.2x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Protagonist Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

31.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTGX's revenue (64.5% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: PTGX's revenue (64.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PTGX is forecast to be unprofitable in 3 years.

Past Performance

How has Protagonist Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-25.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PTGX is currently unprofitable.

Growing Profit Margin: PTGX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: PTGX is unprofitable, and losses have increased over the past 5 years at a rate of 25.2% per year.

Accelerating Growth: Unable to compare PTGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: PTGX has a negative Return on Equity (-40.59%), as it is currently unprofitable.

Financial Health

How is Protagonist Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTGX's short term assets ($341.5M) exceed its short term liabilities ($43.5M).

Long Term Liabilities: PTGX's short term assets ($341.5M) exceed its long term liabilities ($3.1M).

Debt to Equity History and Analysis

Debt Level: PTGX is debt free.

Reducing Debt: PTGX had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTGX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTGX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 32.4% each year.

Dividend

What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTGX has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure

CEO

Dinesh Patel (64 yo)

13.42yrs

Tenure

US$5,544,733

Compensation

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and was its Interim Chief Financial Officer till May 28, 2019. Dr. Patel...

CEO Compensation Analysis

Compensation vs Market: Dinesh's total compensation ($USD5.54M) is above average for companies of similar size in the US market ($USD2.59M).

Compensation vs Earnings: Dinesh's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: PTGX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: PTGX's board of directors are considered experienced (7.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31